Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?

Journal of Human Hypertension

Volumn 14, Issue 3, 2000, Pages 163-170

  Ding, Philip Y A ^a   Hu, O Yoa Pu ^b   Pool, P E ^c   Liao, W C ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c Reno Cardiology Research Laboratory   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Benazepril; Captopril; Chinese; Cilazapril; Enalapril; Ethnicity; Fosinopril; Genetic variations; Lisinopril; Perindopril; Pharmacodynamics; Pharmacokinetics; Spir april

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; ISRADIPINE; LISINOPRIL; NIFEDIPINE; PERINDOPRIL; RHEUM E; RHEUM OFFICINALE EXTRACT; SPIRAPRIL; UNCLASSIFIED DRUG;

CAUCASIAN; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; COUGHING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; PHARMACODYNAMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TACHYCARDIA;

EID: 0034015797     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000856     Document Type: Review

References (53)

1. Zhou H-H et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320: 565-570.
2. Wang JG et al. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996; 10: 735-742.
3. Hall AS, Ball SG. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-687.
4. Rigat B et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
5. Tiret L et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
6. Samani NJ et al. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-712.
7. Singer DR, Missouris CG, Jeffery S. Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion? Circulation 1996; 94: 236-239.
8. Chiang FT et al. Lack of association of the angiotensin converting enzyme polymorphism with essential hypertension in a Chinese population. Am J Hypertens 1997; 10: 197-201.
9. Lee EJ. Population genetics of the angiotensin-converting enzyme in Chinese. Br J Clin Pharmacol 1994; 37: 212-214.
10. Chuang LM et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan. Metabolism 1997; 46: 1211-1214.
11. Jeng JR et al. Angiotensin I converting enzyme gene polymorphism in Chinese patients with hypertension. Am J Hypertens 1997; 10: 558-561.
12. Sanderson JE et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. Am J Cardiol 1996; 77: 1008-1010.
13. Jian M et al. Polymorphism of angiotensin I converting enzyme gene in the older Chinese: linked to ambulatory blood pressure levels and circadian blood pressure rhythm. Int J Cardiol 1996; 55: 33-40.
14. Chiang FT et al. Age- and gender-dependent association of the angiotensin-converting enzyme gene with essential hypertension in a Chinese population. J Hum Hypertens 1996; 10: 823-826.
15. Chiang FT et al. Lack of association between angiotensin-converting enzyme gene polymorphism and coronary heart disease in a Chinese population. Jpn Heart J 1997; 38: 227-236.
16. Saha N et al. Lack of association of angiotensin-converting enzyme (ACE). Gene insertion/deletion polymorphism with CAD in two Asian populations. Clin Genet 1996; 50: 121-125.
17. Jeng JR et al. Angiotensin I converting enzyme gene polymorphism and insulin resistance in patients with hypertension. J Hypertens 1997; 15: 963-968.
18. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 1994; 90: 2207-2212.
19. Caulfield M et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-1633.
20. Ko YL et al. Angiotensinogen and angiotonsin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Hum Genet 1997; 100: 210-214.
21. Cheung B, Leung R. M235T polymorphism of the angiotensinogen gene is not associated with hypertension in Chinese. Circulation 1997; 96 (Suppl): I-227 (abstract #562).
22. Kuivenhoven JA et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.
23. Lee EJ. Polymorphic inhihition of human angiotensin I-converting enzyme by enalaprilat. Eur J Clin Pharmacol 1995; 49: 173-175.
24. Borhani NO et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial [see comments]. J Am Med Assoc 1996; 276: 785-791.
25. Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Hypertens Res 1995; 18: 235-244.
26. Gong L et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.
27. Maisch B et al. Retrospective studies and prospects of therapy for hypertension. Herz 1995; 20: 370-389.
28. Anderson PJ, Critchley JA, Tomlinson B. A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Eur J Clin Pharmacol 1996; 50: 57-62.
29. Ding PYA et al. Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. J Clin Pharmacol 1999; 39: 155-160.
30. Chen J-H et al. Pharmacokinetics of fosinopril in Chinese patients with congestive heart failure. Clin Drug Invest 1998; 16: 377-385.
31. Anderson PJ, Critchley JA, Tomlinson B, Resplandy G. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Br J Clin Pharmacol 1995; 39: 361-368.
32. Waeber B, Brunner HR. Cilazapril. In: Messerli FH (ed). Cardiovascular Drug Therapy. 2nd edn. W.B. Saunders Company: Philadelphia, 1996, pp 810-813.
33. Sica DA. Fosinopril. In: Messerli FH (ed). Cardiovascular Drug Therapy. 2nd edn. W.B. Saunders Company: Philadelphia, 1996, pp 801-809.
34. Kostis JB et al. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Clin Pharmacol Ther 1995; 58: 660-665.
35. Ford NF et al. Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. J Clin Pharmacol 1995; 35: 785-793.
36. Hu OY-P et al. Pharmacokinetics of fosinoprilat in Chinese and Whites after intravenous administration. J Clin Pharmacol 1997; 37: 834-840.
37. Lees KR, Reid JL. Perindopril. In: Messerli FH (ed). Cardiovascular Drug Therapy. 2nd edn. W.B. Saunders Company: Philadelphia, 1996, pp 775-784.
38. Physicians' Desk Reference. Medical Economics Co: Montvale, NJ, 1998, p 2357.
39. O'Grady P, Mangold B, Yeo K-F, Liao W-C. Fosinoprilat and enalaprilat pharmacokinetics in patients with congestive heart failure and renal insufficiency. J Heart Failure 1995; 2: Abstract 1058.
40. Zhang JH, Li LS, Zhang M. Clinical effects of rheum and captopril on preventing progression of chronic renal failure. Chin Med J (Engl) 1990; 103: 788-793.
41. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-144.
42. Chan JC et al. The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM. Diabetes Care 1994; 17: 859-862.
43. Chan P et al. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997; 10: 743-749.
44. Hwang YS, Yen HW. Efficacy of once-daily lisinopril monotherapy in systemic hypertension. Clin Cardiol 1993; 16: 129-132.
45. Chen CH et al. Short-term and long-term effects of benazepril in mild to moderate hypertensives. Chung Hua I Hsueh Tsa Chih (Taipei) 1995; 56: 12-22.
46. Tomlinson B et al. Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. Am J Hypertens 1994; 7: 35S-39S.
47. Chen CH et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995; 25: 1034-1041.
48. Germino FW et al. Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough - a pilot study. Curr Therap Res Clin Exp 1993; 54: 469-475.
49. Punzi HA. Safety update: focus on cough. Am J Cardiol 1993; 72: 45H-48H.
50. Brogden RN, Todd PA, Sorkin EM. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 36: 540-600.
51. Sorooshian M, Eynon CA, Webb DJ, Eastwood JB. Cough associated with angiotensin converting enzyme inhibitors: increased frequency in renal failure. Eur J Int Med 1991; 2: 15-17.
52. Clementy J. Double-blind, randomized study of fosinopril vs nifedipine SR in the treatment of mild-to-moderate hypertension in elderly patients. Drug Invest 1991; 3 (Suppl 4): 45-53.
53. Smithies O. A mouse view of hypertension. Circulation 1997; 30: 1318-1324.